Everyone who sees these photos and is reasonably healthy should pause for a moment and be somewhat humbled and grateful. Often in everyday life you forget how relatively well you are doing and get angry about trivial things and do not enjoy the here and now.
Promising interim results from a Phase 1 study of $ZYME's ZW191 in heavily pretreated patients with PROC.
$GMAB's Rinatabart sesutecan did not achieve such good results in earlier studies.
https://t.co/qIaWxcpGtj
$GILD will acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001 (macrocyclic peptide), from PepStar for $1.275 billion in upfront cash.
This shows once again just how undervalued the Japanese #Peptidream $PPTDF is, given its comprehensive peptide portfolio.
PeptiDream $PPTDF Announces First Patient Dosed in Phase 1 Trial → Radiopharmaceutical Program Targeting Carbonic Anhydrase IX for Kidney Cancer.
Operating performance continues to be at odds with the stock price trend.
https://t.co/THuPOU9NJo
@JulianRoepcke Ihr Urteil ist unzutreffend.
Übernahme russischer Propaganda wäre es, wenn die Medien schrieben, Russland habe die Stadt eingenommen. Die Medien berichten jedoch, Russland habe gemeldet, die Stadt eingenommen zu haben. Dies ist keine Propaganda, sondern objektiver Journalismus.
I think $ZYME's corporate policy of acting as a financial investor in pharmaceutical sectors outside its core business is pretty harebrained.
https://t.co/vS63cih7Tr